PROCRITline.com - Subscribe Today

Portal Home

For reimbursement information regarding other Centocor Ortho Biotech Inc. products, please click here.

PROCRITline.com Reimbursement Excellence

Please see full Prescribing Information, including Boxed WARNINGS, for PROCRIT^® (Epoetin alfa)

Subscribe Today

Sign up for our e-mail alert service that will let you know when PROCRITline.com has summary guideline updates, new information or features. This exciting new service will keep you on top of the latest changes here at PROCRITline.com.

All information will be kept confidential. You may subscribe by using the form below and you may unsubscribe at anytime by using the same form. For more information on this new service, please refer to the details below.

Details

•	This service is referred to as an "opt-in" e-mail alert service since all subscribers voluntarily join and may unsubscribe at any time.
•	If you are an America Online user, you must use your full Internet address. For example, you must use "MyName@aol.com", not just "MyName".
•	Subscriber names will not be sold or given to anyone else. All information remains confidential. For full details, refer to our Privacy Policy.
•	There is no charge for this service.
•	After you complete the above form, you will receive a confirmation e-mail message, welcoming you to this service.
•	Only Centocor Ortho Biotech Inc. personnel will be able to send messages to the subscribers. Subscribers cannot send messages to other subscribers via this service.
R138

Important Safety Information for PROCRIT^® (Epoetin alfa)

WARNINGS: INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE

Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious cardiovascular events, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of 13 g/dL and above.

Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1).

To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusion.

Because of these risks, prescribers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense PROCRIT^® to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

Discontinue following the completion of a chemotherapy course.

Perisurgery: PROCRIT^® (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.

(See WARNINGS: Increased Mortality, Serious Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS: Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence, INDICATIONS AND USAGE, and DOSAGE AND ADMINISTRATION.)

Please see full Prescribing Information, including Boxed WARNINGS for PROCRIT^® (Epoetin alfa)

Medication Guide for PROCRIT^®
Please read the Medication Guide for PROCRIT^® and discuss with your doctor.

Patient Instructions for Use
Instructions if you or your caregiver has been trained to give PROCRIT^® injections at home.